EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 397 filers reported holding EXELIXIS INC in Q3 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63,802 | -34.9% | 2,920 | -43.0% | 0.06% | -29.8% |
| Q2 2023 | $97,939 | -1.5% | 5,125 | 0.0% | 0.08% | -17.6% |
| Q1 2023 | $99,476 | +21.0% | 5,125 | 0.0% | 0.10% | +37.8% |
| Q4 2022 | $82,205 | +2.8% | 5,125 | 0.0% | 0.07% | -1.3% |
| Q3 2022 | $80,000 | +19.4% | 5,125 | +60.2% | 0.08% | +29.3% |
| Q2 2022 | $67,000 | -8.2% | 3,200 | 0.0% | 0.06% | +16.0% |
| Q1 2022 | $73,000 | +25.9% | 3,200 | 0.0% | 0.05% | +42.9% |
| Q4 2021 | $58,000 | -14.7% | 3,200 | 0.0% | 0.04% | -18.6% |
| Q3 2021 | $68,000 | +17.2% | 3,200 | 0.0% | 0.04% | +13.2% |
| Q2 2021 | $58,000 | -38.9% | 3,200 | -23.8% | 0.04% | -42.4% |
| Q1 2021 | $95,000 | +13.1% | 4,200 | 0.0% | 0.07% | +3.1% |
| Q4 2020 | $84,000 | -18.4% | 4,200 | 0.0% | 0.06% | -29.7% |
| Q3 2020 | $103,000 | +119.1% | 4,200 | +110.0% | 0.09% | +97.8% |
| Q2 2020 | $47,000 | -77.7% | 2,000 | -81.4% | 0.05% | -83.2% |
| Q4 2018 | $211,000 | – | 10,725 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 17,416,738 | $422,007,000 | 64.06% |
| Matrix Capital Management Company, LP | 15,117,460 | $366,296,000 | 11.71% |
| Rhenman & Partners Asset Management AB | 1,050,000 | $25,442,000 | 3.25% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 254,334 | $6,163,000 | 2.40% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 790,148 | $19,145,000 | 1.30% |
| Jupiter Investment Management Ltd | 4,182,760 | $101,348,000 | 1.06% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 50,818 | $1,231,000 | 0.70% |
| C M BIDWELL & ASSOCIATES LTD | 17,475 | $423,000 | 0.65% |
| QCM Cayman, Ltd. | 9,562 | $232,000 | 0.60% |
| Handelsinvest Investeringsforvaltning | 98,500 | $2,387,000 | 0.56% |